P53 expression in tumor-stromal fibroblasts forming and not forming fibrotic foci in invasive ductal carcinoma of the breast

Modern Pathology

Volumn 23, Issue 5, 2010, Pages 662-672

  Hasebe, Takahiro ^a   Iwasaki, Motoki ^b   Akashi Tanaka, Sadako ^c   Hojo, Takashi ^c   Shibata, Tatsuhiro ^d   Sasajima, Yuko ^c   Kinoshita, Takayuki ^c   Tsuda, Hitoshi ^d  

^a Center for Cancer Control and Information Services   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Breast; Fibroblast; Fibrotic focus; P53; Tumor cell stromal cell interaction

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST FIBROSIS; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LYMPH VESSEL; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; STROMA CELL; TUMOR CELL; TUMOR EMBOLISM;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; ESTROGEN RECEPTOR ALPHA; FEMALE; FIBROBLASTS; FIBROSIS; HUMANS; IMMUNOHISTOCHEMISTRY; MASTECTOMY; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952010040     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.47     Document Type: Article

References (29)

1. Hasebe T, Tsuda H, Hirohashi S, et al. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat 1998;49:195-208.
2. Hasebe T, Sasaki S, Imoto S, et al. Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study. Mod Pathol 2002;15:502-516.
3. Colpaert C, Vermeulen PB, van Beest P, et al. Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. Histopathology 2001;39:416-425. (Pubitemid 32990095)
4. Baak JP, Colpaert CG, van Diest PJ, et al. Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers. Eur J Cancer 2005;41:2093-2101.
5. Van den Eynden GG, Colpart CG, Couveland A, et al. A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph) angiogenesis in breast cancer: review of the literature and proposal on the criteria of evaluation. Histopathology 2007;51:440-451.
6. Hasebe T, Sasaki S, Imoto S, et al. Proliferative activity of intratumoral fibroblasts is closely correlated with lymph node and distant organ metastases of invasive ductal carcinoma of the breast. Am J Pathol 2000;156:1701-1710.
7. Hasebe T, Sasaki S, Imoto S, et al. Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast. Mod Pathol 2001;14:325-337.
8. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008;14:518-527. (Pubitemid 351655218)
9. Singer CF, Gschwantler-Kaulich D, Fink-Retter A, et al. Differential gene expression profile in breast cancerderived stromal fibroblasts. Breast Cancer Res Treat 2008;110:273-281.
10. Hasegawa M, Furuya M, Kasuya Y, et al. CD151 dynamics in carcinoma-stroma interaction: integrin expression, adhesion strength and proteolytic activity. Lab Invest 2007;87:882-892.
11. Studebaker AW, Storci G, Werbeck JL, et al. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 2008;68:9087-9095.
12. Kurose K, Gilley S, Matsumoto PH, et al. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinoma. Nat Genet 2002;32:355-357.
13. Hill R, Song Y, Cardiff RD, et al. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2006;123:1001-1011.
14. Bierie B, Moses HL. Under pressure: stromal fibroblasts change their ways. Cell 2005;123:985-987.
15. Patocs A, Zhang L, Xu Y, et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 2007;357:2543-2551.
16. Allinen M, Beroukhim R, Cai L, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004;6:17-32. (Pubitemid 38903159)
17. Lebret SC, Newgreen DF, Thompson EW, et al. Induction of epithelial to mesenchymal transition in PMC42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors. Breast Cancer Res 2007;9: R19.
18. Campbell IG, Qiu W, Polyak K, et al. Breast-cancer stromal cells with TP53 mutations. N Engl J Med 2008;10:1634-1635.
19. Hasebe T, Okada N, Tamura N, et al. p53 expression in tumor-stromal fibroblasts is closely associated with the outcome of patients with invasive ductal carcinoma. Cancer Sci 2009;100:2101-2108.
20. Hasebe T, Tamura N, Okada N, et al. p53 expression in tumor-stromal fibroblasts is closely associated with the nodal metastasis and outcome of patients with invasive ductal carcinoma who received neoadjuvant therapy. Hum Pathol 2010;41:262-270.
21. Hasebe T, Yamauchi C, Iwasaki M, et al. Grading system for lymph vessel tumor emboli for prediction of the outcome of invasive ductal carcinoma of the breast. Hum Pathol 2008;39:427-436.
22. Hasebe T, Okada N, Iwasaki M, et al. Grading system for lymph vessel tumor emboli: significant outcome predictor for invasive ductal carcinoma of the breast. Hum Pathol 2010 (in press).
23. Sobin LH, Wittekind Ch, (eds). TNM Classification of Malignant Tumors 6th edn. Wiley-Liss: Geneva, 2002, pp 131-141.
24. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359-377.
25. Gilchrist KW, Gray R, Fowble B, et al. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. J Clin Oncol 1993;11:1929-1935.
26. Harvey JM, Clark GM, Osborne K, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481.
27. Mohsin S, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 2004;17:1545-1554.
28. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-206.
29. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43.